The OTX-TKI study is a phase 1 open-label, dose escalation study of OTX-TKI (axitinib implant) for intravitreal use in subjects with neovascular Age-related macular degeneration (AMD).

Study Type  : Interventional  (Clinical Trial)
Actual Enrollment  : 21 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: 3:1
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Prospective Multicenter, Double-Masked, Randomized, Parallel-Group, Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI (Axitinib Implant) for Intravitreal Use in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Actual Study Start Date  : July 28, 2021
Estimated Primary Completion Date  : September 2022
Estimated Study Completion Date  : December 2022

Related Publications

Our Affiliates